Improvement of nonalcoholic fatty liver disease in ALT  at ≥12 months after Roux-en-Y gastric bypass and sleeve gastrectomy, no effect in ALT and AST at < 12 months after SG and in AST at > 12 and ≤24 months after RYGB

We read with great interest about the amelioration of nonalcoholic fatty liver disease (NAFLD) undergoing Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). Recently, there was a meta-analysis by Baldwin et  al. [1] suggesting that RYGB and SG had a reduction in alanine transaminase (ALT) compared with baseline level (mean difference [MD]: −12.3, 95% confidence interval [CI]: −16.0, −8.6; MD: −16.5, 95%CI: −25.7, −7.2, respectively). The reduction in aspartate aminotransferase (AST) underg oing RYGB or SG was also obtained compared with baseline levels (MD: −3.6, 95%CI: −5.9, −1.3; MD: −8.1, 95%CI: −14.9, −1.4, respectively).
Source: Surgery for Obesity and Related Diseases - Category: Surgery Authors: Tags: Letter to the editor Source Type: research